Table 1.
454 sequencing of EGFR exon 20. About 100,000 454 reads per sample were generated from PCR products generated with EGFR exon 20 (ex20)–spanning primers. All tumors were from treatment-naïve patients. TKI-R-1 and TKI-R-2 were run as positive control samples. 1°mutn, primary EGFR mutation, as assessed by direct sequencing.
| Sample | Stage | 1°mutn | 454 ex20 T790M (%) |
|---|---|---|---|
| Lung TKI-R-1 | IV | 19 DEL | Y (59%) |
| Lung TKI-R-2 | IV | L858R | Y (1.07%) |
| H3255 | Cell Line | L858R | N |
| PC-9 | Cell Line | 19 DEL | N |
| 130T | IA | 19 DEL | N |
| 169T | IA | 19 DEL | N |
| 230T | IA | 19 DEL | N |
| 474T | IA | 19 DEL | N |
| 631T | IA | 19 DEL | N |
| 20T | IB | 19 DEL | N |
| 734T | IB | 19 DEL | N |
| 739T | IB | 19 DEL | N |
| 388T | IIIA | 19 DEL | N |
| 3T | IA | L858R | N |
| 5T | IA | L858R | N |
| 485T | IA | L858R | N |
| 570T | IB | L858R | N |
| 685T | IB | L858R | N |
| 25T | IB | L858R | N |
| 166T | IB | L858R | N |